A review of the potential mechanisms for the lowering of colorectal oncogenesis by butyrate

British Journal of Nutrition

Volumn 108, Issue 5, 2012, Pages 820-831

  Fung, Kim Y C ^a   Cosgrove, Leah ^a   Lockett, Trevor ^a   Head, Richard ^a   Topping, David L ^a  

^a CSIRO   (Australia)

Author keywords

Butyrate; Colorectal cancer; Fibre; Resistant starch; SCFA

Indexed keywords

BUTYRIC ACID; CARRIER PROTEINS AND BINDING PROTEINS; G PROTEIN COUPLED RECEPTOR 109A; G PROTEIN COUPLED RECEPTOR 43; GLUCOSE TRANSPORTER 1; HISTONE DEACETYLASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCARBOXYLATE TRANSPORTER 1; PROTEIN SCFA; PROTEIN SLC5A8; RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BUTYRIC ACID DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL DESTRUCTION; CARCINOGENESIS; CELL CYCLE ARREST; CELL METABOLISM; CELLULAR STRESS RESPONSE; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; EPIGENETICS; GENETIC REGULATION; GENOMIC INSTABILITY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; APOPTOSIS; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG EFFECT; PATHOLOGY;

ANTICARCINOGENIC AGENTS; APOPTOSIS; BUTYRATES; CELL PROLIFERATION; COLORECTAL NEOPLASMS; HUMANS;

EID: 84871883810     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114512001948     Document Type: Review

References (124)

1. Ferlay J, Shin HR, Bray F, et al. (2010) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [ Internet]. Lyon: International Agency for Research on Cancer.
2. Center MM, Jemal A, Smith RA, et al. (2009) Worldwide variations in colorectal cancer. CA Cancer J Clin 59, 366-378.
3. Parkin DM, Bray F, Ferlay J, et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108.
4. Haggar FA & Boushey RP (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 22, 191-197.
5. Wong MT & Eu KW (2007) Rise of colorectal cancer in Singapore: an epidemiological review. ANZ J Surg 77, 446-449.
6. World Cancer Research Fund & American Institute for Cancer Research (2007) Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR.
7. Platz EA, Willett WC, Colditz GA, et al. (2000) Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control 11, 579-588.
8. Bingham SA, Day NE, Luben R, et al. (2003) Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 361, 1496-1501.
9. Park Y, Hunter DJ, Spiegelman D, et al. (2005) Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA 294, 2849-2857.
10. McCullough ML, Robertson AS, Chao A, et al. (2003) A prospective study of whole grains, fruits, vegetables and colon cancer risk. Cancer Causes Control 14, 959-970.
11. Brouns F, Kettlitz B & Arrigoni E (2002) Resistant starch and 'the butyrate revolution'. Trends Food Sci Technol 13, 251-261.
12. Topping DL & Clifton PM (2001) Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 81, 1031-1064.
13. Bugaut M (1987) Occurrence, absorption and metabolism of short chain fatty acids in the digestive tract of mammals. Comp Biochem Physiol B 86, 439-472.
14. Freudenheim JL, Graham S, Horvath PJ, et al. (1990) Risks associated with source of fiber and fiber components in cancer of the colon and rectum. Cancer Res 50, 3295-3300.
15. Stephen AM & Cummings JH (1980) Mechanism of action of dietary fibre in the human colon. Nature 284, 283-284.
16. Marlett JA (1992) Content and composition of dietary fiber in 117 frequently consumed foods. J Am Diet Assoc 92, 175-186.
17. Topping D (2007) Cereal complex carbohydrates and their contribution to human health. J Cer Sci 46, 220-229.
18. Ahmed R, Segal I & Hassan H (2000) Fermentation of dietary starch in humans. Am J Gastroenterol 95, 1017-1020.
19. Cummings JH (1984) Colonic absorption: the importance of short chain fatty acids in man. Scand J Gastroenterol Suppl 93, 89-99.
20. Perrin P, Pierre F, Patry Y, et al. (2001) Only fibres promoting a stable butyrate producing colonic ecosystem decrease the rate of aberrant crypt foci in rats. Gut 48, 53-61.
21. Clarke JM, Topping DL, Bird AR, et al. (2008) Effects of high-amylose maize starch and butyrylated high-amylose maize starch on azoxymethane-induced intestinal cancer in rats. Carcinogenesis 29, 2190-2194.
22. Le Leu RK, Hu Y, Brown IL, et al. (2009) Effect of high amylose maize starches on colonic fermentation and apoptotic response to DNA-damage in the colon of rats. Nutr Metab (Lond) 6, 11.
23. Toden S, Bird AR, Topping DL, et al. (2007) Dosedependent reduction of dietary protein-induced colonocyte DNA damage by resistant starch in rats correlates more highly with caecal butyrate than with other short chain fatty acids. Cancer Biol Ther 6, 253-258.
24. Lewin MH, Bailey N, Bandaletova T, et al. (2006) Red meat enhances the colonic formation of the DNA adduct O6-carboxymethyl guanine: implications for colorectal cancer risk. Cancer Res 66, 1859-1865.
25. Tan SL, Gerber JP, Cosgrove LJ, et al. (2011) Is the tissue persistence of O(6)-methyl-20-deoxyguanosine an indicator of tumour formation in the gastrointestinal tract Mutat Res 721, 119-126.
26. Kampman E, Voskuil DW, van Kraats AA, et al. (2000) Animal products and K-ras codon 12 and 13 mutations in colon carcinomas. Carcinogenesis 21, 307-309.
27. Slattery ML, Curtin K, Anderson K, et al. (2000) Associations between dietary intake and Ki-ras mutations in colon tumors: a population-based study. Cancer Res 60, 6935-6941.
28. Daly K & Shirazi-Beechey SP (2006) Microarray analysis of butyrate regulated genes in colonic epithelial cells. DNA Cell Biol 25, 49-62.
29. Fung KY, Brierley GV, Henderson ST, et al. (2011) Butyrateinduced apoptosis in HCT116 colorectal cancer cells includes induction of a cell stress response. J Proteome Res 10, 1860-1869.
30. Fung KY, Lewanowitsch T, Henderson ST, et al. (2009) Proteomic analysis of butyrate effects and loss of butyrate sensitivity in HT29 colorectal cancer cells. J Proteome Res 8, 1220-1227.
31. Iacomino G, Tecce MF, Grimaldi C, et al. (2001) Transcriptional response of a human colon adenocarcinoma cell line to sodium butyrate. Biochem Biophys Res Commun 285, 1280-1289.
32. Tan HT, Tan S, Lin Q, et al. (2008) Quantitative and temporal proteome analysis of butyrate-treated colorectal cancer cells. Mol Cell Proteomics 7, 1174-1185.
33. Tan S, Seow TK, Liang RC, et al. (2002) Proteome analysis of butyrate-treated human colon cancer cells (HT-29). Int J Cancer 98, 523-531.
34. Olmo N, Turnay J, Perez-Ramos P, et al. (2007) In vitro models for the study of the effect of butyrate on human colon adenocarcinoma cells. Toxicol In Vitro 21, 262-270.
35. Lopez de Silanes I, Olmo N, Turnay J, et al. (2004) Acquisition of resistance to butyrate enhances survival after stress and induces malignancy of human colon carcinoma cells. Cancer Res 64, 4593-4600.
36. Serpa J, Caiado F, Carvalho T, et al. (2010) Butyrate-rich colonic microenvironment is a relevant selection factor for metabolically adapted tumor cells. J Biol Chem 285, 39211-39223.
37. Kim YH, Park JW, Lee JY, et al. (2004) Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 25, 1813-1820.
38. Pajak B, Gajkowska B & Orzechowski A (2009) Sodium butyrate sensitizes human colon adenocarcinoma COLO 205 cells to both intrinsic and TNF-alpha-dependent extrinsic apoptosis. Apoptosis 14, 203-217.
39. Shao Y, Gao Z, Marks PA, et al. (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101, 18030-18035.
40. Tang Y, Chen Y, Jiang H, et al. (2011) The role of shortchain fatty acids in orchestrating two types of programmed cell death in colon cancer. Autophagy 7, 235-237.
41. Wang L, Luo HS & Xia H (2009) Sodium butyrate induces human colon carcinoma HT-29 cell apoptosis through a mitochondrial pathway. J Int Med Res 37, 803-811.
42. Avivi-Green C, Polak-Charcon S, Madar Z, et al. (2002) Different molecular events account for butyrate-induced apoptosis in two human colon cancer cell lines. J Nutr 132, 1812-1818.
43. Ruemmele FM, Dionne S, Qureshi I, et al. (1999) Butyrate mediates Caco-2 cell apoptosis via up-regulation of proapoptotic BAK and inducing caspase-3 mediated cleavage of poly-(ADP-ribose) polymerase (PARP). Cell Death Differ 6, 729-735.
44. Scott DW, Longpre JM & Loo G (2008) Upregulation of GADD153 by butyrate: involvement of MAPK. DNA Cell Biol 27, 607-614.
45. Tong C, Yin Z, Song Z, et al. (2007) c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression. Am J Pathol 171, 297-303.
46. Zhang Y, Zhou L, Bao YL, et al. (2010) Butyrate induces cell apoptosis through activation of JNK MAP kinase pathway in human colon cancer RKO cells. Chem Biol Interact 185, 174-181.
47. Yonezawa T, Kobayashi Y & Obara Y (2007) Shortchain fatty acids induce acute phosphorylation of the p38 mitogen-activated protein kinase/heat shock protein 27 pathway via GPR43 in the MCF-7 human breast cancer cell line. Cell Signal 19, 185-193.
48. Wilson AJ, Chueh AC, Togel L, et al. (2010) Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res 70, 609-620.
49. Waby JS, Chirakkal H, Yu C, et al. (2010) Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol Cancer 9, 275.
50. White NR, Mulligan P, King PJ, et al. (2006) Sodium butyrate-mediated Sp3 acetylation represses human insulinlike growth factor binding protein-3 expression in intestinal epithelial cells. J Pediatr Gastroenterol Nutr 42, 134-141.
51. Janson W, Brandner G & Siegel J (1997) Butyrate modulates DNA-damage-induced p53 response by induction of p53-independent differentiation and apoptosis. Oncogene 15, 1395-1406.
52. Gope R & Gope ML (1993) Effect of sodium butyrate on the expression of retinoblastoma (RB1) and P53 gene and phosphorylation of retinoblastoma protein in human colon tumor cell line HT29. Cell Mol Biol (Noisy-le-grand) 39, 589-597.
53. Nakano K, Mizuno T, Sowa Y, et al. (1997) Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 272, 22199-22206.
54. Yuan ZM, Huang Y, Ishiko T, et al. (1999) Role for p300 in stabilization of p53 in the response to DNA damage. J Biol Chem 274, 1883-1886.
55. Terui T, Murakami K, Takimoto R, et al. (2003) Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res 63, 8948-8954.
56. Hu S, Dong TS, Dalal SR, et al. (2011) The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PLoS One 6, e16221.
57. Zhang H, Li W, Nan F, et al. (2011) MicroRNA expression profile of colon cancer stem-like cells in HT29 adenocarcinoma cell line. Biochem Biophys Res Commun 404, 273-278.
58. Necela BM, Carr JM, Asmann YW, et al. (2011) Differential expression of microRNAs in tumors from chronically inflamed or genetic (APC) models of colon cancer. PLoS One 6, e18501.
59. Breuer RI, Buto SK, Christ ML, et al. (1991) Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Preliminary report. Dig Dis Sci 36, 185-187.
60. Breuer RI, Soergel KH, Lashner BA, et al. (1997) Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut 40, 485-491.
61. Scheppach W, Sommer H, Kirchner T, et al. (1992) Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 103, 51-56.
62. Huang N, Katz JP, Martin DR, et al. (1997) Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine 9, 27-36.
63. Stempelj M, Kedinger M, Augenlicht L, et al. (2007) Essential role of the JAK/STAT1 signaling pathway in the expression of inducible nitric-oxide synthase in intestinal epithelial cells and its regulation by butyrate. J Biol Chem 282, 9797-9804.
64. Rosignoli P, Fabiani R, De Bartolomeo A, et al. (2001) Protective activity of butyrate on hydrogen peroxide-induced DNA damage in isolated human colonocytes and HT29 tumour cells. Carcinogenesis 22, 1675-1680.
65. Sauer J, Richter KK & Pool-Zobel BL (2007) Physiological concentrations of butyrate favorably modulate genes of oxidative and metabolic stress in primary human colon cells. J Nutr Biochem 18, 736-745.
66. Ebert MN, Klinder A, Peters WH, et al. (2003) Expression of glutathione S-transferases (GSTs) in human colon cells and inducibility of GSTM2 by butyrate. Carcinogenesis 24, 1637-1644.
67. Tong X, Yin L & Giardina C (2004) Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition. Biochem Biophys Res Commun 317, 463-471.
68. Jahns F, Wilhelm A, Jablonowski N, et al. (2011) Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue. Carcinogenesis 32, 913-920.
69. Greten FR, Eckmann L, Greten TF, et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296.
70. Sakamoto K, Maeda S, Hikiba Y, et al. (2009) Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res 15, 2248-2258.
71. Chen C, Edelstein LC & Gelinas C (2000) The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 20, 2687-2695.
72. Zong WX, Edelstein LC, Chen C, et al. (1999) The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 13, 382-387.
73. Li H, Myeroff L, Smiraglia D, et al. (2003) SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA 100, 8412-8417.
74. Thangaraju M, Cresci G, Itagaki S, et al. (2008) Sodiumcoupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer. J Gastrointest Surg 12, 1773-1781, discussion 1781-1772.
75. Thangaraju M, Gopal E, Martin PM, et al. (2006) SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res 66, 11560-11564.
76. Vinolo MA, Rodrigues HG, Hatanaka E, et al. (2011) Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem 22, 849-855.
77. Bailon E, Cueto-Sola M, Utrilla P, et al. (2010) Butyrate in vitro immune-modulatory effects might be mediated through a proliferation-related induction of apoptosis. Immunobiology 215, 863-873.
78. Vinolo MA, Rodrigues HG, Hatanaka E, et al. (2009) Shortchain fatty acids stimulate the migration of neutrophils to inflammatory sites. Clin Sci (Lond) 117, 331-338.
79. Fukuda S, Toh H, Hase K, et al. (2011) Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469, 543-547.
80. Brown AJ, Goldsworthy SM, Barnes AA, et al. (2003) The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 278, 11312-11319.
81. Le Poul E, Loison C, Struyf S, et al. (2003) Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 278, 25481-25489.
82. Nilsson NE, Kotarsky K, Owman C, et al. (2003) Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun 303, 1047-1052.
83. Aoyama M, Kotani J & Usami M (2010) Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. Nutrition 26, 653-661.
84. Maslowski KM, Vieira AT, Ng A, et al. (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282-1286.
85. Sina C, Gavrilova O, Forster M, et al. (2009) G proteincoupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol 183, 7514-7522.
86. Tang Y, Chen Y, Jiang H, et al. (2011) G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer. Int J Cancer 128, 847-856.
87. Soga T, Kamohara M, Takasaki J, et al. (2003) Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 303, 364-369.
88. Tunaru S, Kero J, Schaub A, et al. (2003) PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9, 352-355.
89. Wise A, Foord SM, Fraser NJ, et al. (2003) Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 278, 9869-9874.
90. Ahmed K, Tunaru S & Offermanns S (2009) GPR109A, GPR109B and GPR81, a family of hydroxy-carboxylic acid receptors. Trends Pharmacol Sci 30, 557-562.
91. Taggart AK, Kero J, Gan X, et al. (2005) (D)-Beta-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 280, 26649-26652.
92. Thangaraju M, Cresci GA, Liu K, et al. (2009) GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res 69, 2826-2832.
93. Warburg O (1956) On the origin of cancer cells. Science 123, 309-314.
94. Cairns RA, Harris IS & Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11, 85-95.
95. Emenaker NJ & Basson MD (2001) Short chain fatty acids differentially modulate cellular phenotype and c-myc protein levels in primary human nonmalignant and malignant colonocytes. Dig Dis Sci 46, 96-105.
96. Wilson AJ, Velcich A, Arango D, et al. (2002) Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res 62, 6006-6010.
97. Pellizzaro C, Coradini D& DaidoneMG(2002) Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29. Carcinogenesis 23, 735-740.
98. Zgouras D, Wachtershauser A, Frings D, et al. (2003) Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1alpha nuclear translocation. Biochem Biophys Res Commun 300, 832-838.
99. Koukourakis MI, Giatromanolaki A, Harris AL, et al. (2006) Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 66, 632-637.
100. Pinheiro C, Longatto-Filho A, Scapulatempo C, et al. (2008) Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch 452, 139-146.
101. Andriamihaja M, Chaumontet C, Tome D, et al. (2009) Butyrate metabolism in human colon carcinoma cells: implications concerning its growth-inhibitory effect. J Cell Physiol 218, 58-65.
102. Tamai I, Takanaga H, Maeda H, et al. (1995) Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids. Biochem Biophys Res Commun 214, 482-489.
103. Lambert DW, Wood IS, Ellis A, et al. (2002) Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. Br J Cancer 86, 1262-1269.
104. Borthakur A, Saksena S, Gill RK, et al. (2008) Regulation of monocarboxylate transporter 1 (MCT1) promoter by butyrate in human intestinal epithelial cells: involvement of NF-kappaB pathway. J Cell Biochem 103, 1452-1463.
105. Haber RS, Rathan A, Weiser KR, et al. (1998) GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 83, 34-40.
106. Kim JW, Gao P & Dang CV (2007) Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev 26, 291-298.
107. Yun J, Rago C, Cheong I, et al. (2009) Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325, 1555-1559.
108. Blouin JM, Penot G, Collinet M, et al. (2011) Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex. Int J Cancer 128, 2591-2601.
109. Newton IP, Kenneth NS, Appleton PL, et al. (2010) Adenomatous polyposis coli and hypoxia-inducible factor-1{alpha} have an antagonistic connection. Mol Biol Cell 21, 3630-3638.
110. Williamson PA, Pols RG, Illman RJ, et al. (1987) Blood carbonmonoxyhaemoglobin levels are chronically elevated in alcoholics treated for detoxification. Atherosclerosis 67, 245-250.
111. Topping DL, Fishlock RC, Trimble RP, et al. (1981) Carboxyhaemoglobin inhibits the metabolism of ethanol by perfused rat liver. Biochem Int 3, 157-163.
112. Gardner RS, Topping DL & Mayes PA (1978) Immediate effects of carbon monoxide on the metabolism of chylomicron remnants by perfused rat liver. Biochem Biophys Res Commun 82, 526-531.
113. Mann BS, Johnson JR, Cohen MH, et al. (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12, 1247-1252.
114. Fang JY, Chen YX, Lu J, et al. (2004) Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116. Cell Res 14, 217-226.
115. Kang SN, Lee E, Lee MK, et al. (2011) Preparation and evaluation of tributyrin emulsion as a potent anti-cancer agent against melanoma. Drug Deliv 18, 143-149.
116. Kuroiwa-Trzmielina J, de Conti A, Scolastici C, et al. (2009) Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug. Int J Cancer 124, 2520-2527.
117. Li Y, Le Maux S, Xiao H, et al. (2009) Emulsion-based delivery systems for tributyrin, a potential colon cancer preventative agent. J Agric Food Chem 57, 9243-9249.
118. Miyoshi M, Sakaki H, Usami M, et al. (2011) Oral administration of tributyrin increases concentration of butyrate in the portal vein and prevents lipopolysaccharide-induced liver injury in rats. Clin Nutr 30, 252-258.
119. Ooi CC, Good NM, Williams DB, et al. (2010) Structure-activity relationship of butyrate analogues on apoptosis, proliferation and histone deacetylase activity in HCT-116 human colorectal cancer cells. Clin Exp Pharmacol Physiol 37, 905-911.
120. Ooi CC, Good NM, Williams DB, et al. (2010) Efficacy of butyrate analogues in HT-29 cancer cells. Clin Exp Pharmacol Physiol 37, 482-489.
121. Cassidy A, Bingham SA & Cummings JH (1994) Starch intake and colorectal cancer risk: an international comparison. Br J Cancer 69, 937-942.
122. Bird AR, Vuaran MS, King RA, et al. (2008) Wholegrain foods made from a novel high-amylose barley variety (Himalaya 292) improve indices of bowel health in human subjects. Br J Nutr 99, 1032-1040.
123. McOrist AL, Miller RB, Bird AR, et al. (2011) Fecal butyrate levels vary widely among individuals but are usually increased by a diet high in resistant starch. J Nutr 141, 883-889.
124. Cummings JH, Beatty ER, Kingman SM, et al. (1996) Digestion and physiological properties of resistant starch in the human large bowel. Br J Nutr 75, 733-747.